Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Intech Investment Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) in ...

Today, Benzinga's options scanner spotted 25 options trades for Teva Pharmaceutical Indus. This is not a typical pattern. The sentiment among these major traders is split, with 24% bullish and 60% ...

Daiwa Securities Group Inc. lifted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 10.0% ...

SPACE is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous administration of fremanezumab versus ...

Teva Pharmaceutical Industries Limited’s TEVA stock has declined 10% in a month despite strong third-quarter results announced earlier this month. The company beat estimates for earnings as well ...

A tiny company in a fast-growing industry is a recipe for millionaire-making potential. And with shares up by a whopping 347% ...